MiNK Therapeutics Surges to 19th in Daily Rankings with 24.50 Billion Turnover

On July 11, 2025, MiNK Therapeutics (INKT) experienced a significant surge in trading volume, with a total turnover of 24.50 billion, marking an impressive 11957996.26% increase from the previous day. This surge placed MiNK Therapeutics at the 19th position in the daily stock market rankings. The company's stock price soared by 730.14%, marking the fourth consecutive day of gains, with a cumulative increase of 815.41% over the past four days.

MiNK Therapeutics recently announced the publication of a groundbreaking case study in Nature's Oncogene, detailing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer. This landmark case involved a patient who had progressed despite multiple lines of therapy and received a single infusion of agenT-797, MiNK's allogeneic iNKT cell therapy, in combination with Bristol-Myers Squibb Company’s Opdivo (nivolumab). The patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later. Donor iNKT cells were detectable up to six months post-infusion, and the treatment was well-tolerated with no cytokine release syndrome (CRS) or graft-versus-host disease (GVHD).

These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors. At the 2025 inaugural AACR Immuno-Oncology meeting, MiNK presented data from its Phase 2 trial in second-line (2L) gastric cancer, demonstrating immune activation, increased tumor infiltration, and early signals of tumor control in patients previously refractory to checkpoint inhibitors. Several patients experienced extended survival beyond 12 months. These clinical observations were further reinforced in a separate peer-reviewed case report published in Oncogene, which described a patient with metastatic gastric cancer who achieved a 42% tumor reduction and more than nine months of progression-free survival following a single infusion of agenT-797 in combination with nivolumab. The ongoing Phase 2 trial in gastric cancer is actively enrolling, and additional readouts are expected in the upcoming months.